;PMID: 11238048
;source_file_581.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:41..156] = [t:41..156]
;2)section:[e:160..218] = [t:160..218]
;3)section:[e:222..419] = [t:222..419]
;4)sentence:[e:423..485] = [t:423..485]
;5)sentence:[e:486..621] = [t:486..621]
;6)sentence:[e:622..955] = [t:622..955]
;7)sentence:[e:957..1091] = [t:957..1091]
;8)sentence:[e:1092..1287] = [t:1092..1287]
;9)sentence:[e:1288..1423] = [t:1288..1423]
;10)sentence:[e:1424..1512] = [t:1424..1512]
;11)sentence:[e:1514..1697] = [t:1514..1697]
;12)sentence:[e:1698..1810] = [t:1698..1810]
;13)sentence:[e:1811..1964] = [t:1811..1964]
;14)sentence:[e:1965..2123] = [t:1965..2123]
;15)sentence:[e:2124..2275] = [t:2124..2275]
;16)section:[e:2279..2324] = [t:2279..2324]

;section 0 Span:0..36
;Am J Pathol  2001 Mar;158(3):1005-10
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..11] Pathol) (CD:[13..17] 2001)
        (CC:[18..24] Mar;15) (CD:[24..25] 8) (NN:[25..26] -LRB-) (NN:[26..27] 3)
        (-RRB-:[27..28] -RRB-) (VBZ:[28..29] :) (CD:[29..32] 100)
        (CD:[32..36] 5-10)))

;sentence 1 Span:41..156
;Sporadic fundic gland polyps: common gastric polyps arising through
;activating  mutations in the beta-catenin gene.
;[41..69]:malignancy:"Sporadic fundic gland polyps"
;[71..92]:malignancy:"common gastric polyps"
;[138..150]:gene-rna:"beta-catenin"
(SENT
  (NP-HLN
    (NP (JJ:[41..49] Sporadic)
      (NML (JJ:[50..56] fundic) (NN:[57..62] gland))
      (NNS:[63..69] polyps))
    (::[69..70] :)
    (NP
      (NP (JJ:[71..77] common) (JJ:[78..85] gastric) (NNS:[86..92] polyps))
      (VP (VBG:[93..100] arising)
        (PP (IN:[101..108] through)
          (NP
            (NP (VBG:[109..119] activating) (NNS:[121..130] mutations))
            (PP (IN:[131..133] in)
              (NP (DT:[134..137] the) (NN:[138..150] beta-catenin)
                  (NN:[151..155] gene)))))))
    (.:[155..156] .)))

;section 2 Span:160..218
;Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT.
(SEC
  (FRAG (NNP:[160..167] Abraham) (NNP:[168..170] SC) (,:[170..171] ,)
        (NNP:[172..180] Nobukawa) (NNP:[181..182] B) (,:[182..183] ,)
        (NNP:[184..194] Giardiello) (NNP:[195..197] FM) (,:[197..198] ,)
        (NNP:[199..207] Hamilton) (NNP:[208..210] SR) (,:[210..211] ,)
        (NNP:[212..214] Wu) (NNP:[215..218] TT.)))

;section 3 Span:222..419
;Department of Pathology, Division of Gastroenterology, The Johns Hopkins 
;University School of Medicine, Ross Building, Room 632, 720 Rutland Ave., 
;Baltimore, MD 21205-2196, USA. sabraham@jhmi.edu
(SEC
  (FRAG (NNP:[222..232] Department) (IN:[233..235] of)
        (NNP:[236..245] Pathology) (,:[245..246] ,) (NNP:[247..255] Division)
        (IN:[256..258] of) (NNP:[259..275] Gastroenterology) (,:[275..276] ,)
        (DT:[277..280] The) (NNP:[281..286] Johns) (NNP:[287..294] Hopkins)
        (NNP:[296..306] University) (NNP:[307..313] School) (IN:[314..316] of)
        (NNP:[317..325] Medicine) (,:[325..326] ,) (NNP:[327..331] Ross)
        (NNP:[332..340] Building) (,:[340..341] ,) (NNP:[342..346] Room)
        (CD:[347..350] 632) (,:[350..351] ,) (CD:[352..355] 720)
        (NNP:[356..363] Rutland) (NNP:[364..367] Ave) (NN:[367..368] .)
        (,:[368..369] ,) (NNP:[371..380] Baltimore) (,:[380..381] ,)
        (NNP:[382..384] MD) (CD:[385..389] 2120) (CD:[389..395] 5-2196)
        (,:[395..396] ,) (NNP:[397..400] USA) (.:[400..401] .)
        (IN:[402..415] sabraham@jhmi) (NN:[415..419] .edu)))

;sentence 4 Span:423..485
;Fundic gland polyps (FGPs) are the most common gastric polyps.
;[423..442]:malignancy:"Fundic gland polyps"
;[444..448]:malignancy:"FGPs"
;[470..484]:malignancy:"gastric polyps"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (JJ:[423..429] Fundic) (NN:[430..435] gland))
        (NNS:[436..442] polyps))
      (NP (-LRB-:[443..444] -LRB-) (NNS:[444..448] FGPs)
          (-RRB-:[448..449] -RRB-)))
    (VP (VBP:[450..453] are)
      (NP-PRD (DT:[454..457] the)
        (ADJP (RBS:[458..462] most) (JJ:[463..469] common))
         (JJ:[470..477] gastric) (NNS:[478..484] polyps)))
    (.:[484..485] .)))

;sentence 5 Span:486..621
;FGPs  traditionally have been regarded as nondysplastic hamartomatous or
;hyperplastic  lesions, but their pathogenesis remains unclear.
;[486..490]:malignancy:"FGPs"
;[528..555]:malignancy:"nondysplastic hamartomatous"
;[559..580]:malignancy:"hyperplastic  lesions"
(SENT
  (S
    (S
      (NP-SBJ-2 (NNS:[486..490] FGPs))
      (ADVP (RB:[492..505] traditionally))
      (VP (VBP:[506..510] have)
        (VP (VBN:[511..515] been)
          (VP (VBN:[516..524] regarded)
            (NP-2 (-NONE-:[524..524] *))
            (PP (IN:[525..527] as)
              (NP
                (NP
                   (JJ:[528..541] nondysplastic) (JJ:[542..555] hamartomatous)
                  (NML-1 (-NONE-:[555..555] *P*)))
                (CC:[556..558] or)
                (NP (JJ:[559..571] hyperplastic)
                  (NML-1 (NNS:[573..580] lesions)))))))))
    (,:[580..581] ,) (CC:[582..585] but)
    (S
      (NP-SBJ (PRP$:[586..591] their) (NN:[592..604] pathogenesis))
      (VP (VBZ:[605..612] remains)
        (ADJP-PRD (JJ:[613..620] unclear))))
    (.:[620..621] .)))

;sentence 6 Span:622..955
;We have recently shown that  somatic adenomatous polyposis coli (APC) gene
;alterations are frequently present  in FGPs associated with familial
;adenomatous polyposis (FAP), raising the  possibility that mutations of the
;beta-catenin gene affecting the  APC/beta-catenin pathway might be involved
;in the pathogenesis of sporadic FGPs.
;[659..685]:gene-rna:"adenomatous polyposis coli"
;[687..690]:gene-rna:"APC"
;[736..740]:malignancy:"FGPs"
;[757..787]:malignancy:"familial adenomatous polyposis"
;[789..792]:malignancy:"FAP"
;[842..854]:gene-rna:"beta-catenin"
;[875..878]:gene-rna:"APC"
;[879..891]:gene-rna:"beta-catenin"
;[941..954]:malignancy:"sporadic FGPs"
(SENT
  (S
    (NP-SBJ (PRP:[622..624] We))
    (VP (VBP:[625..629] have)
      (ADVP-TMP (RB:[630..638] recently))
      (VP (VBN:[639..644] shown)
        (SBAR (IN:[645..649] that)
          (S
            (NP-SBJ (JJ:[651..658] somatic)
              (NML
                (NML (JJ:[659..670] adenomatous) (NN:[671..680] polyposis)
                     (NN:[681..685] coli))
                (NML (-LRB-:[686..687] -LRB-) (NN:[687..690] APC)
                     (-RRB-:[690..691] -RRB-)))
              (NN:[692..696] gene) (NNS:[697..708] alterations))
            (VP (VBP:[709..712] are)
              (ADVP-TMP (RB:[713..723] frequently))
              (ADJP-PRD (JJ:[724..731] present)
                (PP (IN:[733..735] in)
                  (NP
                    (NP (NNS:[736..740] FGPs))
                    (VP (JJ:[741..751] associated)
                      (NP (-NONE-:[751..751] *))
                      (PP-CLR (IN:[752..756] with)
                        (NP
                          (NP (JJ:[757..765] familial)
                              (JJ:[766..777] adenomatous)
                              (NN:[778..787] polyposis))
                          (NP (-LRB-:[788..789] -LRB-) (NN:[789..792] FAP)
                              (-RRB-:[792..793] -RRB-)))))))))))
        (,:[793..794] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[794..794] *))
          (VP (VBG:[795..802] raising)
            (NP (DT:[803..806] the) (NN:[808..819] possibility)
              (SBAR (IN:[820..824] that)
                (S
                  (NP-SBJ-1
                    (NP
                      (NP (NNS:[825..834] mutations))
                      (PP (IN:[835..837] of)
                        (NP (DT:[838..841] the) (NN:[842..854] beta-catenin)
                            (NN:[855..859] gene))))
                    (VP (VBG:[860..869] affecting)
                      (NP (DT:[870..873] the)
                        (NML (NN:[875..878] APC) (SYM:[878..879] /)
                             (NN:[879..891] beta-catenin))
                        (NN:[892..899] pathway))))
                  (VP (MD:[900..905] might)
                    (VP (VB:[906..908] be)
                      (VP (JJ:[909..917] involved)
                        (NP-1 (-NONE-:[917..917] *))
                        (PP-CLR (IN:[918..920] in)
                          (NP
                            (NP (DT:[921..924] the) (NN:[925..937] pathogenesis))
                            (PP (IN:[938..940] of)
                              (NP (JJ:[941..949] sporadic) (NNS:[950..954] FGPs)))))))))))))))
    (.:[954..955] .)))

;sentence 7 Span:957..1091
;We analyzed somatic beta-catenin gene mutations in 57 sporadic FGPs from 40 
;patients without FAP and in 19 FGPs from 13 FAP patients.
;[977..989]:gene-rna:"beta-catenin"
;[1011..1024]:malignancy:"sporadic FGPs"
;[1051..1054]:malignancy:"FAP"
;[1065..1069]:malignancy:"FGPs"
;[1078..1081]:malignancy:"FAP"
(SENT
  (S
    (NP-SBJ (PRP:[957..959] We))
    (VP (VBD:[960..968] analyzed)
      (NP (JJ:[969..976] somatic) (NN:[977..989] beta-catenin)
          (NN:[990..994] gene) (NNS:[995..1004] mutations))
      (PP-LOC
        (PP (IN:[1005..1007] in)
          (NP
            (NP (CD:[1008..1010] 57)
               (JJ:[1011..1019] sporadic) (NNS:[1020..1024] FGPs))
            (PP (IN:[1025..1029] from)
              (NP
                (NP (CD:[1030..1032] 40) (NNS:[1034..1042] patients))
                (PP (IN:[1043..1050] without)
                  (NP (NN:[1051..1054] FAP)))))))
        (CC:[1055..1058] and)
        (PP (IN:[1059..1061] in)
          (NP
            (NP (CD:[1062..1064] 19) (NNS:[1065..1069] FGPs))
            (PP (IN:[1070..1074] from)
              (NP (CD:[1075..1077] 13) (NN:[1078..1081] FAP)
                  (NNS:[1082..1090] patients)))))))
    (.:[1090..1091] .)))

;sentence 8 Span:1092..1287
;Direct DNA sequencing  of exon 3 encompassing the glycogen synthase
;kinase-3beta phosphorylation region  for beta-catenin was used with
;confirmation by HIN:fI restriction endonuclease  digestion.
;[1118..1124]:variation-location:"exon 3"
;[1142..1195]:variation-location:"glycogen synthase kinase-3beta
;phosphorylation region"
;[1201..1213]:gene-rna:"beta-catenin"
;[1244..1275]:gene-protein:"HIN:fI restriction endonuclease"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (JJ:[1092..1098] Direct) (NN:[1099..1102] DNA)
            (NN:[1103..1113] sequencing))
        (PP (IN:[1115..1117] of)
          (NP (NN:[1118..1122] exon) (CD:[1123..1124] 3))))
      (VP (VBG:[1125..1137] encompassing)
        (NP
          (NP (DT:[1138..1141] the)
            
            (NML (NN:[1142..1150] glycogen) (NN:[1151..1159] synthase))
            (NN:[1160..1172] kinase-3beta) (NN:[1173..1188] phosphorylation)
             (NN:[1189..1195] region))
          (PP (IN:[1197..1200] for)
            (NP (NN:[1201..1213] beta-catenin))))))
    (VP (VBD:[1214..1217] was)
      (VP (VBN:[1218..1222] used)
        (NP-1 (-NONE-:[1222..1222] *))
        (PP (IN:[1223..1227] with)
          (NP
            (NP (NN:[1228..1240] confirmation))
            (PP (IN:[1241..1243] by)
              (NP
                 (NN:[1244..1250] HIN:fI)
                (NML (NN:[1251..1262] restriction)
                     (NN:[1263..1275] endonuclease))
                (NN:[1277..1286] digestion)))))))
    (.:[1286..1287] .)))

;sentence 9 Span:1288..1423
;The foveolar epithelium and dilated fundic glands of the polyps were 
;separately microdissected and analyzed in 22 of 57 sporadic FGPs.
;[1292..1311]:malignancy:"foveolar epithelium"
;[1316..1351]:malignancy:"dilated fundic glands of the polyps"
;[1409..1422]:malignancy:"sporadic FGPs"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1288..1291] The)
         (JJ:[1292..1300] foveolar) (NN:[1301..1311] epithelium))
      (CC:[1312..1315] and)
      (NP
        (NP (JJ:[1316..1323] dilated) (JJ:[1324..1330] fundic)
            (NNS:[1331..1337] glands))
        (PP (IN:[1338..1340] of)
          (NP (DT:[1341..1344] the) (NNS:[1345..1351] polyps)))))
    (VP (VBD:[1352..1356] were)
      (ADVP-MNR (RB:[1358..1368] separately))
      (VP (VBN:[1369..1383] microdissected) (CC:[1384..1387] and)
          (VBN:[1388..1396] analyzed)
        (NP-1 (-NONE-:[1396..1396] *))
        (PP (IN:[1397..1399] in)
          (NP
            (NP (CD:[1400..1402] 22))
            (PP (IN:[1403..1405] of)
              (NP (CD:[1406..1408] 57)
                 (JJ:[1409..1417] sporadic) (NNS:[1418..1422] FGPs)))))))
    (.:[1422..1423] .)))

;sentence 10 Span:1424..1512
;Activating  beta-catenin gene mutations were present in 91% (52 of 57) of
;sporadic FGPs.
;[1436..1448]:gene-rna:"beta-catenin"
;[1498..1511]:malignancy:"sporadic FGPs"
(SENT
  (S
    (NP-SBJ (VBG:[1424..1434] Activating) (NN:[1436..1448] beta-catenin)
            (NN:[1449..1453] gene) (NNS:[1454..1463] mutations))
    (VP (VBD:[1464..1468] were)
      (ADJP-PRD (JJ:[1469..1476] present)
        (PP (IN:[1477..1479] in)
          (NP
            (NP (CD:[1480..1482] 91) (NN:[1482..1483] %)
              (PRN (-LRB-:[1484..1485] -LRB-)
                (NP
                  (NP (CD:[1485..1487] 52))
                  (PP (IN:[1488..1490] of)
                    (NP (CD:[1491..1493] 57))))
                (-RRB-:[1493..1494] -RRB-)))
            (PP (IN:[1495..1497] of)
              (NP (JJ:[1498..1506] sporadic) (NNS:[1507..1511] FGPs)))))))
    (.:[1511..1512] .)))

;sentence 11 Span:1514..1697
;Both the foveolar epithelium and the dilated fundic gland epithelium
;comprising  the polyps were shown to have the same somatic beta-catenin
;mutation in 21 of 22  (95%) sporadic FGPs.
;[1523..1542]:malignancy:"foveolar epithelium"
;[1551..1605]:malignancy:"dilated fundic gland epithelium comprising  the
;polyps"
;[1642..1654]:gene-rna:"beta-catenin"
;[1683..1696]:malignancy:"sporadic FGPs"
(SENT
  (S
    (NP-SBJ-1 (CC:[1514..1518] Both)
      (NP (DT:[1519..1522] the)
         (JJ:[1523..1531] foveolar) (NN:[1532..1542] epithelium))
      (CC:[1543..1546] and)
      (NP
        (NP (DT:[1547..1550] the) (JJ:[1551..1558] dilated)
          (NML (JJ:[1559..1565] fundic) (NN:[1566..1571] gland))
          (NN:[1572..1582] epithelium))
        (VP (VBG:[1583..1593] comprising)
          (NP (DT:[1595..1598] the) (NNS:[1599..1605] polyps)))))
    (VP (VBD:[1606..1610] were)
      (VP (VBN:[1611..1616] shown)
        (S
          (NP-SBJ-1 (-NONE-:[1616..1616] *))
          (VP (TO:[1617..1619] to)
            (NP (VB:[1620..1624] have)
              (NP (DT:[1625..1628] the) (JJ:[1629..1633] same)
                  (JJ:[1634..1641] somatic) (NN:[1642..1654] beta-catenin)
                  (NN:[1655..1663] mutation))
              (PP (IN:[1664..1666] in)
                (NP
                  (NP (CD:[1667..1669] 21))
                  (PP (IN:[1670..1672] of)
                    (NP (CD:[1673..1675] 22)
                      (PRN (-LRB-:[1677..1678] -LRB-)
                        (NP (CD:[1678..1680] 95) (NN:[1680..1681] %))
                        (-RRB-:[1681..1682] -RRB-))
                       (JJ:[1683..1691] sporadic) (NNS:[1692..1696] FGPs))))))))))
    (.:[1696..1697] .)))

;sentence 12 Span:1698..1810
;In contrast, beta-catenin gene mutations were not present  in any of the 19
;FAP-associated FGPs (P: < 0.000001).
;[1711..1723]:gene-rna:"beta-catenin"
;[1774..1793]:malignancy:"FAP-associated FGPs"
(SENT
  (S
    (PP (IN:[1698..1700] In)
      (NP (NN:[1701..1709] contrast)))
    (,:[1709..1710] ,)
    (NP-SBJ (NN:[1711..1723] beta-catenin) (NN:[1724..1728] gene)
            (NNS:[1729..1738] mutations))
    (VP (VBD:[1739..1743] were) (RB:[1744..1747] not)
      (ADJP-PRD (JJ:[1748..1755] present)
        (PP (IN:[1757..1759] in)
          (NP
            (NP (DT:[1760..1763] any))
            (PP (IN:[1764..1766] of)
              (NP (DT:[1767..1770] the) (CD:[1771..1773] 19)
                
                (ADJP (NN:[1774..1777] FAP) (HYPH:[1777..1778] -)
                      (VBN:[1778..1788] associated))
                (NNS:[1789..1793] FGPs))))))
      (PRN (-LRB-:[1794..1795] -LRB-)
        (S
          (NP-SBJ (NN:[1795..1796] P))
          (::[1796..1797] :)
          (VP (SYM:[1798..1799] <)
            (NP (CD:[1800..1808] 0.000001))))
        (-RRB-:[1808..1809] -RRB-)))
    (.:[1809..1810] .)))

;sentence 13 Span:1811..1964
;The high frequency of  beta-catenin mutations in sporadic FGPs indicates that
;these lesions arise  through activating mutations of the beta-catenin gene.
;[1834..1846]:gene-rna:"beta-catenin"
;[1860..1873]:malignancy:"sporadic FGPs"
;[1889..1902]:malignancy:"these lesions"
;[1946..1958]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1811..1814] The) (JJ:[1815..1819] high)
          (NN:[1820..1829] frequency))
      (PP (IN:[1830..1832] of)
        (NP
          (NP (NN:[1834..1846] beta-catenin) (NNS:[1847..1856] mutations))
          (PP-LOC (IN:[1857..1859] in)
            (NP (JJ:[1860..1868] sporadic) (NNS:[1869..1873] FGPs))))))
    (VP (VBZ:[1874..1883] indicates)
      (SBAR (IN:[1884..1888] that)
        (S
          (NP-SBJ (DT:[1889..1894] these) (NNS:[1895..1902] lesions))
          (VP (VBP:[1903..1908] arise)
            (PP (IN:[1910..1917] through)
              (NP
                (NP (VBG:[1918..1928] activating) (NNS:[1929..1938] mutations))
                (PP (IN:[1939..1941] of)
                  (NP (DT:[1942..1945] the) (NN:[1946..1958] beta-catenin)
                      (NN:[1959..1963] gene)))))))))
    (.:[1963..1964] .)))

;sentence 14 Span:1965..2123
;Beta-catenin mutations in  gastrointestinal tract polyps have previously only
;been demonstrated in a subset  of adenomatous (dysplastic) or neoplastic
;polyps.
;[1965..1977]:gene-rna:"Beta-catenin"
;[1992..2021]:malignancy:"gastrointestinal tract polyps"
;[2077..2101]...[2116..2122]:malignancy-type:"adenomatous
;(dysplastic)"..."polyps"
;[2105..2122]:malignancy-type:"neoplastic polyps"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[1965..1977] Beta-catenin) (NNS:[1978..1987] mutations))
      (PP (IN:[1988..1990] in)
        (NP
          (NML (JJ:[1992..2008] gastrointestinal) (NN:[2009..2014] tract))
          (NNS:[2015..2021] polyps))))
    (VP (VBP:[2022..2026] have)
      (ADVP-TMP (RB:[2027..2037] previously))
      (ADVP (RB:[2038..2042] only))
      (VP (VBN:[2043..2047] been)
        (VP (VBN:[2048..2060] demonstrated)
          (NP-2 (-NONE-:[2060..2060] *))
          (PP (IN:[2061..2063] in)
            (NP
              (NP (DT:[2064..2065] a) (NN:[2066..2072] subset))
              (PP (IN:[2074..2076] of)
                (NP
                  (NP (JJ:[2077..2088] adenomatous)
                    (PRN (-LRB-:[2089..2090] -LRB-)
                      (ADJP (JJ:[2090..2100] dysplastic))
                      (-RRB-:[2100..2101] -RRB-))
                    (NML-1 (-NONE-:[2101..2101] *P*)))
                  (CC:[2102..2104] or)
                  (NP (JJ:[2105..2115] neoplastic)
                    (NML-1 (NNS:[2116..2122] polyps))))))))))
    (.:[2122..2123] .)))

;sentence 15 Span:2124..2275
;Sporadic FGPs are therefore  the only lesions of the gastrointestinal tract
;to demonstrate beta-catenin  mutations while lacking dysplastic morphology.
;[2124..2137]:malignancy:"Sporadic FGPs"
;[2162..2199]:malignancy:"lesions of the gastrointestinal tract"
;[2215..2227]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ (JJ:[2124..2132] Sporadic) (NNS:[2133..2137] FGPs))
    (VP (VBP:[2138..2141] are)
      (ADVP (RB:[2142..2151] therefore))
      (NP-PRD
        (NP
          (NP (DT:[2153..2156] the) (JJ:[2157..2161] only)
              (NNS:[2162..2169] lesions))
          (PP (IN:[2170..2172] of)
            (NP (DT:[2173..2176] the) (JJ:[2177..2193] gastrointestinal)
                (NN:[2194..2199] tract))))
        (SBAR
          (WHNP-1 (-NONE-:[2199..2199] 0))
          (S
            (NP-SBJ-1 (-NONE-:[2199..2199] *T*))
            (VP (TO:[2200..2202] to)
              (VP (VB:[2203..2214] demonstrate)
                (NP (NN:[2215..2227] beta-catenin) (NNS:[2229..2238] mutations))
                (SBAR-ADV (IN:[2239..2244] while)
                  (S
                    (NP-SBJ (-NONE-:[2244..2244] *))
                    (VP (VBG:[2245..2252] lacking)
                      (NP (JJ:[2253..2263] dysplastic)
                          (NN:[2264..2274] morphology)))))))))))
    (.:[2274..2275] .)))

;section 16 Span:2279..2324
;PMID: 11238048 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2279..2283] PMID) (::[2283..2284] :) (CD:[2285..2293] 11238048)
        (NN:[2294..2295] -LSB-) (NNP:[2295..2301] PubMed) (::[2302..2303] -)
        (NN:[2304..2311] indexed) (IN:[2312..2315] for)
        (NNP:[2316..2324] MEDLINE-RSB-)))
